Table 1.
Baseline characteristics
| Patient characteristic | Frequency (%) | Median (range) |
|---|---|---|
| Sex | ||
| Male | 12 (70.6%) | |
| Female | 5 (29.4%) | |
| Age (years) | 14 (8–18) | |
| Pathologic diagnosis (CNS WHO 2021 classification) | ||
| Diffuse pediatric-type high-grade glioma, H3-wild-type and IDH-wild-type | 12 (70.6%) | |
| Diffuse hemispheric glioma, H3 G34-mutant | 4 (23.5%) | |
| Diffuse non-midline glioma, H3 K27M-mutant NEC | 1 (5.9%) | |
| Primary site | ||
| Hemispheric | 15 (88.2%) | |
| Thalamus | 1 (5.9%) | |
| Spinal | 1 (5.9%) | |
| Metastatic disease | ||
| Yes | 7 (41.2%) | |
| No | 10 (58.8%) | |
| First line treatment | ||
| Yes | 15 (88.2%) | |
| No | 2 (11.8%) |
H3 histone 3, IDH isocitrate dehydrogenase, NEC not elsewhere classified